Alvotech WT (ALVOW)

$3.41 +0.36 (11.80%)
Market Cap N/A
Revenue (ttm) 91.43M
Net Income (ttm) -551.73M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 11,000
Avg Vol 4,012
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 73%
Beta N/A
Analysts Sell
Price Target N/A

Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indicatio...

Address:
9, Rue de Bitbourg, Luxembourg City, Luxembourg
Latest News on ALVOW
Alvotech further strengthens liquidity by securing term loan facility of $75 million

Jul 1, 2026, 4:00 AM EDT - 10 hours ago

Alvotech further strengthens liquidity by securing term loan facility of $75 million

Transactions of Managers and Closely Associated Persons

Jun 22, 2026, 6:48 PM EDT - 8 days ago

Transactions of Managers and Closely Associated Persons

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

Jun 18, 2026, 4:00 AM EDT - 13 days ago

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

Jun 18, 2026, 4:00 AM EDT - 13 days ago

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

Alvotech $152M Spot Secondary priced at $3.75

2026-06-16T11:08:35.000Z - 15 days ago

Alvotech $152M Spot Secondary priced at $3.75

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

Jun 15, 2026, 11:50 PM EDT - 15 days ago

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

Alvotech TBA Spot Secondary; price range $3.75-$undefined

2026-06-15T22:30:37.000Z - 15 days ago

Alvotech TBA Spot Secondary; price range $3.75-$undefined

Alvotech announces termination of ATM Prospectus Supplement with Jefferies

2026-06-15T20:46:20.000Z - 15 days ago

Alvotech announces termination of ATM Prospectus Supplement with Jefferies

JEF

Alvotech Transcript: UBS Virtual Generics and Biosimilars Day

Jun 10, 2026, 10:30 AM EDT - 21 days ago

Alvotech Transcript: UBS Virtual Generics and Biosimilars Day

Alvotech Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:40 AM EDT - 23 days ago

Alvotech Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Alvotech announces FDA acceptance of AVT16 BLA for review

2026-06-08T09:20:28.000Z - 23 days ago

Alvotech announces FDA acceptance of AVT16 BLA for review

TEVA

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

Jun 8, 2026, 4:00 AM EDT - 23 days ago

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

Alvotech Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 9:20 AM EDT - 27 days ago

Alvotech Transcript: Jefferies Global Healthcare Conference 2026

Alvotech resubmits AVT05 BLAs to FDA

2026-06-04T09:10:13.000Z - 27 days ago

Alvotech resubmits AVT05 BLAs to FDA

RDY TEVA

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Jun 4, 2026, 4:00 AM EDT - 27 days ago

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Main Results of 2026 Annual and Extraordinary General Meeting

Jun 3, 2026, 4:30 PM EDT - 27 days ago

Main Results of 2026 Annual and Extraordinary General Meeting

Alvotech to present at upcoming investor conferences in June

Jun 2, 2026, 4:30 PM EDT - 4 weeks ago

Alvotech to present at upcoming investor conferences in June

Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland

Jun 1, 2026, 4:30 AM EDT - 4 weeks ago

Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland

Alvotech Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 6:40 PM EDT - 6 weeks ago

Alvotech Transcript: Bank of America Global Healthcare Conference 2026

Alvotech announces cGMP surveillance inspection of Reykjavik facility

2026-05-11T09:25:06.000Z - 7 weeks ago

Alvotech announces cGMP surveillance inspection of Reykjavik facility

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

May 11, 2026, 4:30 AM EDT - 7 weeks ago

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

Alvotech Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 7 weeks ago

Alvotech Earnings Call Transcript: Q1 2026

Alvotech Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 7 weeks ago

Alvotech Earnings release: Q1 2026

Alvotech Slides: Q1 2026

May 7, 2026, 8:00 AM EDT - 7 weeks ago

Alvotech Slides: Q1 2026

Alvotech Q1 2026 Financial Results

May 6, 2026, 4:30 PM EDT - 7 weeks ago

Alvotech Q1 2026 Financial Results

Alvotech Announces a Change in its Executive Team

Apr 30, 2026, 4:30 PM EDT - 2 months ago

Alvotech Announces a Change in its Executive Team

Alvotech to Report Financial Results for the First Quarter of 2026

Apr 24, 2026, 8:30 AM EDT - 2 months ago

Alvotech to Report Financial Results for the First Quarter of 2026

Alvotech files Annual Report with the SEC

Mar 30, 2026, 7:58 PM EDT - 3 months ago

Alvotech files Annual Report with the SEC

Alvotech Publishes 2025 Annual Report

Mar 30, 2026, 7:55 PM EDT - 3 months ago

Alvotech Publishes 2025 Annual Report

Alvotech price target lowered to $4 from $8 at Deutsche Bank

2026-03-24T12:50:32.000Z - 3 months ago

Alvotech price target lowered to $4 from $8 at Deutsche Bank

Alvotech price target lowered to $4 from $5 at Barclays

2026-03-24T09:37:15.000Z - 3 months ago

Alvotech price target lowered to $4 from $5 at Barclays

Alvotech price target lowered to $6 from $10 at UBS

2026-03-23T23:30:12.000Z - 3 months ago

Alvotech price target lowered to $6 from $10 at UBS

Alvotech price target lowered to $4 from $5 at Barclays

2026-03-23T18:55:10.000Z - 3 months ago

Alvotech price target lowered to $4 from $5 at Barclays

Alvotech Earnings Call Transcript: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 3 months ago

Alvotech Earnings Call Transcript: Q4 2025

Alvotech Annual report: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 3 months ago

Alvotech Annual report: Q4 2025

Alvotech Earnings release: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 3 months ago

Alvotech Earnings release: Q4 2025

Alvotech Slides: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 3 months ago

Alvotech Slides: Q4 2025

Alvotech Q4 2025 and Full Year 2025 Financial Results

Mar 18, 2026, 6:15 PM EDT - 3 months ago

Alvotech Q4 2025 and Full Year 2025 Financial Results

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Mar 4, 2026, 3:00 AM EST - 4 months ago

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Alvotech Announces Increase in Number of Own Shares

Feb 11, 2026, 11:00 AM EST - 5 months ago

Alvotech Announces Increase in Number of Own Shares

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Feb 5, 2026, 3:00 AM EST - 5 months ago

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Feb 2, 2026, 3:00 AM EST - 5 months ago

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Alvotech Slides: SEB Nordic Seminar presentation

Jan 8, 2026, 7:00 AM EST - 6 months ago

Alvotech Slides: SEB Nordic Seminar presentation

Correction: Transactions of Managers and Closely Associated Persons

Jan 7, 2026, 5:00 PM EST - 6 months ago

Correction: Transactions of Managers and Closely Associated Persons

Alvotech CEO Robert Wessman to step down, Lisa Graver to succeed

2026-01-06T12:21:28.000Z - 6 months ago

Alvotech CEO Robert Wessman to step down, Lisa Graver to succeed

Alvotech Secures Term Loan Facility of USD 100 Million

Dec 31, 2025, 4:30 PM EST - 6 months ago

Alvotech Secures Term Loan Facility of USD 100 Million

Changes in company's own shares

Dec 29, 2025, 2:40 PM EST - 6 months ago

Changes in company's own shares

Alvotech's Financial Calendar for 2026

Dec 22, 2025, 3:26 PM EST - 6 months ago

Alvotech's Financial Calendar for 2026

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

Dec 22, 2025, 2:00 AM EST - 6 months ago

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06

2025-12-19T10:06:47.000Z - 6 months ago

Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06

REGN TEVA

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

Dec 17, 2025, 2:30 AM EST - 7 months ago

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

Alvotech Transcript: Investor Update

Dec 16, 2025, 12:00 PM EST - 7 months ago

Alvotech Transcript: Investor Update

Alvotech Press release: Investor Update

Dec 16, 2025, 12:00 PM EST - 7 months ago

Alvotech Press release: Investor Update

Alvotech initiated with an Underweight at Barclays

2025-12-08T21:25:13.000Z - 7 months ago

Alvotech initiated with an Underweight at Barclays

Alvotech price target lowered to $10 from $14 at Morgan Stanley

2025-12-03T11:53:22.000Z - 7 months ago

Alvotech price target lowered to $10 from $14 at Morgan Stanley

Alvotech announces European Commission approval for AVT03

2025-11-24T10:35:12.000Z - 7 months ago

Alvotech announces European Commission approval for AVT03

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Nov 24, 2025, 5:30 AM EST - 7 months ago

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Nov 20, 2025, 4:00 AM EST - 7 months ago

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Alvotech Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 10:30 AM EST - 8 months ago

Alvotech Transcript: Jefferies London Healthcare Conference 2025

Alvotech price target lowered to $10 from $13 at UBS

2025-11-18T14:36:54.000Z - 8 months ago

Alvotech price target lowered to $10 from $13 at UBS

Alvotech Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:00 AM EST - 8 months ago

Alvotech Earnings Call Transcript: Q3 2025

Alvotech Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 8 months ago

Alvotech Earnings release: Q3 2025

Alvotech Slides: Q3 2025

Nov 13, 2025, 8:00 AM EST - 8 months ago

Alvotech Slides: Q3 2025

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Nov 12, 2025, 4:40 PM EST - 8 months ago

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 10, 2025, 5:28 PM EST - 8 months ago

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 6, 2025, 6:28 PM EST - 8 months ago

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Nov 6, 2025, 9:07 AM EST - 8 months ago

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Nov 4, 2025, 4:01 PM EST - 8 months ago

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Alvotech price target lowered to $10 from $28 at Northland

2025-11-04T13:20:38.000Z - 8 months ago

Alvotech price target lowered to $10 from $28 at Northland

Deutsche downgrades Alvotech on AVT05 complete response letter

2025-11-04T10:00:10.000Z - 8 months ago

Deutsche downgrades Alvotech on AVT05 complete response letter

Alvotech downgraded to Hold from Buy at Deutsche Bank

2025-11-04T01:05:28.000Z - 8 months ago

Alvotech downgraded to Hold from Buy at Deutsche Bank

Alvotech falls -34.2%

2025-11-03T17:05:42.000Z - 8 months ago

Alvotech falls -34.2%

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Nov 2, 2025, 5:12 PM EST - 8 months ago

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Oct 22, 2025, 5:00 AM EDT - 9 months ago

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Oct 6, 2025, 4:40 AM EDT - 9 months ago

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

Sep 22, 2025, 6:15 AM EDT - 10 months ago

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Sep 22, 2025, 4:30 AM EDT - 10 months ago

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Sep 19, 2025, 7:45 AM EDT - 10 months ago

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Alvotech Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 10:45 AM EDT - 10 months ago

Alvotech Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Sep 4, 2025, 9:15 AM EDT - 10 months ago

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Aug 21, 2025, 4:30 AM EDT - 11 months ago

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®